In keeping with its policy of putting the results of pre-clinical work in the public domain for review by scientists, ReNeuron Group Plc (LON:RENE) has published positive data regarding its cell therapy for retinitis pigmentosa (RP), an inherited disease that can cause blindness.
Michael Hunt, chief financial officer (CFO), tells Proactive Investors that ReNeuron “is very keen to put what we do in the public domain … where the data are available for review by others."
The publication relates to data that was part of the pre-clinical package that was put before the US Food and Drug Administration (FDA); ReNeuron recently kicked off a Phase I/II clinical trial in the US to evaluate the safety, tolerability and preliminary efficacy of its human retinal progenitor cells.
“It’s quite a small initial first-in-man study,” Hunt revealed, adding that these sorts of studies normally are small.
“We’re sort of off the starting blocks and we’re treating patients now,” the CFO said.
Hunt also reiterates some previously announced timelines on the US study. RP has been given orphan status, so the clinical development pathway should be swifter than it is for what might be termed more mainstream drugs.